Abstract:Objective:To compare the efficacy of concurrent chemoradiotherapy with temozolomide (TMZ) followed by adjuvant TMZ vs. that without adjuvant TMZ in the treatment of pediatric diffuse intrinsic pontine glioma (DIPG). Methods:The clinical data of 85 children with DIPG who were treated in the Comprehensive Oncology Center, Guangdong Sanjiu Brain Hospital from January 2010 to March 2020 were retrospectively analyzed. All patients received conventional fractionated radiotherapy (total dose 50-54 Gy/27-33 f) combined with temozolomide(75 mg·m -2·d -1) chemotherapy. Then according to the guardians, patients received or not 6 cycles temozolomide chemotherapy one month later after concurrent chemo-radiotherapy. All patients were divided into radiotherapy + concurrent TMZ + adjuvant TMZ group (66 cases), radiotherapy + concurrent TMZ group (19 cases). The Kaplan-Meier curve was drawn to compare the difference in survival time between the two groups. According to the Common Terminology Criteria for Adverse Events Version 4.0 (CTCAE 4.0), the differences in adverse drug reactions between the two groups were evaluated. Results:The median follow-up time of the 85 patients was 9 months (3-28 months), and the overall median survival time was 9 months. The median survival time of the radiotherapy + concurrent TMZ + adjuvant TMZ group was 10 months, and that of the radiotherapy + concurrent TMZ group was 6 months. The log-rank test showed that the difference in survival time between the two groups was statistically significant ( P=0.002). Among the 85 children, 30 (35.3%) had hematological adverse reactions, all of which were CTCAE grades 1-3. There were 24 cases (36.4%) in the radiotherapy + concurrent TMZ + adjuvant TMZ group of 66 cases, including 15 cases of grade 1, 8 cases of grade 2 and 1 case of grade 3. Among the 19 patients in the radiotherapy + concurrent TMZ group, 6 patients (31.6%) developed adverse hematologic reactions, all of which were grade 1. There was no significant difference in the rate of adverse reactions of the hematological system between the two groups ( P=0.255). Conclusion:Compared with concurrent chemoradiotherapy with TMZ alone, that followed by adjuvant TMZ can prolong the survival time of children with DIPG without increasing the incidence of adverse drug reactions.

Prospective Study of Chemo-Radiation Therapy Versus Radiation Therapy Alone in the Treatment of Diffuse Intrinsic Brain Stem Glioma

ACTR-14. A PROSPECTIVE RANDOMIZED STUDY OF CONCURRENT CHEMORADIOTHERAPY WITH TEMOZOLOMIDE VERSUS RADIOTHERAPY ALONE IN PATIENTS WITH IDH WILD-TYPE/TERT PROMOTER MUTATION GRADE II/III GLIOMAS

Clinical study of three -dimension conformal radiation therapy combined with temozolomide after high grade glioma surgery

Efficacy of radiotherapy combined with temozolomide in the treatment of pediatric diffuse intrinsic pontine glioma

CTNI-30. THERAPEUTIC EFFECTS OF RADIOTHERAPY WITH CONCOMITANT AND ADJUVANT TEMOZOLOMIDE VERSUS RADIOTHERAPY WITH CONCOMITANT TEMOZOLOMIDE ALONE IN CHILDREN WITH DIPG: A SINGLE-CENTER EXPERIENCE WITH 82 CASES

RETROSPECTIVE ANALYSIS OF USING RADIOTHERAPY WITH CONCURRENT TEMOZOLOMIDE AND TUMOR TREATING FIELDS FOR CHINESE PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA

Radiotherapy combined with temozolomide treatment for glioblastoma multiforme:a meta-analysis

Post-operative Efficacy of Chemo-Radiotherapy and Prognosis Analysis on 112 Cases of High-Grade Gliomas

Clinical efficacy of temozolomide concomitant radiotherapy and chemoradiotherapy for post-operative glioblastoma

TIPS-05 ADJUVANT TEMOZOLOMIDE CHEMOTHERAPY FOLLOWING RADIOTHERAPY IN NEWLY DIAGNOSED LOW-GRADE GLIOMA PATIENT WITH RESIDUE TUMORS: A MULTICENTER, OPEN LABEL, RANDOMIZED TRIAL

Benefits Afforded by Combined Temozolomide, Radiation and Stem Cell Strategy for Glioma Therapy

Evaluation of the Efficacy of Radiotherapy Concurrent Temozolomide Chemotherapy in Patients with Brain Metastases

An prognostic analysis of hypofractionated radiation plus Temozolomide for newly diagnosed glioblastoma in eld-erlies

Clinical Effect of Temozolomid Combined with Concurrent Radiotherapy on High Grade Intracranial Glioma

[Comparison of Two Regimens of Postoperative Concurrent Chemoradiotherapy in Adult Patients with Grade III-IV Cerebral Gliomas].

RBIO-02. THERAPEUTIC EFFECTS OF RADIOTHERAPY WITH CONCOMITANT IN CHILDREN WITH DIPG

Temozolomide with or without Radiotherapy in Patients with Newly Diagnosed Glioblastoma Multiforme: A Meta-Analysis

Radiotherapy Versus Radiotherapy Combined with Temozolomide in High-Risk Low-Grade Gliomas after Surgery: Study Protocol for a Randomized Controlled Clinical Trial

Efficacy and Toxicity of Different Target Volume Delineations of Radiotherapy Based on the Updated RTOG/NRG and EORTC Guidelines in Patients with High Grade Glioma: A Randomized, Controlled Clinical Trial.

Radiotherapy Concomitant with Temozolomide for Glioblastoma Multiforme

Survival and Prognostic Factors in Patients with Glioblastoma Multiforme Receiving Radiation and Temozolomide – A Retrospective Study